Thomas B. Smith, M.D. has been named vice president, medical affairs, Kendle. Dr. Smith will develop and lead the company's new global medical affairs organization, aimed at enhancing delivery of Phase II-IV services worldwide. This team of medical directors will serve as medical and therapeutic advisors to customers in areas such as protocol design, endpoint selection and inclusion/exclusion criteria, providing a resource across the clinical development process in an effort to create efficiencies and maximize opportunities as a compound progresses through study and its lifecycle.

Dr. Smith most recently served as global medical director for Kendle, responsible for providing strategic medical and therapeutic leadership to clinical development projects with a particular emphasis in the Central Nervous System (CNS) therapeutic area.
   
Dr. Smith joined the company with 20 years of experience in clinical practice and the pharmaceutical industry, including positions as senior director, clinical R&D, at Akros Pharma, medical director, global R&D at Genzyme Corp., and associate medical director, neuroscience global pharmaceuticals R&D, at Abbott Laboratories.  
   
"This move further positions Kendle as a strategic partner for our customers across the clinical development process as they focus on maximizing the therapeutic potential for their compounds," said Candace Kendle, Pharm.D., chairman and chief executive officer. "With an increasing focus on novel drugs like TNF blockers and the multiple therapeutic possibilities these proteins bring, Kendle's Medical Affairs organization will provide a competitive advantage by offering expertise across the full therapeutic spectrum. We are thrilled to have someone of Dr. Smith’s caliber to lead the growth of this valuable resource within Kendle."